{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:15:33Z","timestamp":1783412133723,"version":"3.54.6"},"reference-count":216,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cancer remains a major global health challenge, and traditional treatments often involve significant toxicity and limited benefits for patients with advanced-stage disease. mRNA vaccines have recently emerged as a promising approach in cancer immunotherapy due to their flexibility in design, rapid production, and suitability for personalized treatment. This review summarizes the molecular basis, main classifications, and mechanisms of action of mRNA vaccines for cancer therapy and systematically discusses progress in strategies for delivering tumor-specific antigens, tumor-associated antigens, and immunomodulatory factors. Special attention is given to advances in delivery technologies, especially lipid nanoparticle (LNP) systems, and their potential applications across various cancers. We suggest that the effectiveness of mRNA cancer vaccines depends not only on selecting the right antigens but also on delivery methods that modulate the immune response and reshape the tumor microenvironment. Melanoma is a prime candidate for prioritizing the research and development of mRNA cancer vaccines, given the current clinical landscape. Furthermore, major challenges that continue to limit progress include insufficient stability, suboptimal delivery efficiency, uncontrolled immunogenicity, and the difficulty of overcoming tumor heterogeneity. This review aims to serve as a useful reference for further development and clinical translation of mRNA cancer vaccines.<\/jats:p>","DOI":"10.3389\/fphar.2026.1852041","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:29:50Z","timestamp":1783409390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation"],"prefix":"10.3389","volume":"17","author":[{"given":"Dianzhe","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Eight-Year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinshi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Pharmaceutical Sciences of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuyi","family":"Yang","sequence":"additional","affiliation":[{"name":"Eight-Year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Key Laboratory of Ocular Fundus Disease, Chinese Academy of Medical Sciences","place":["Beijing, China"]},{"name":"Department of Ophthalmology, Peking Union Medical College Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Ocular Fundus Disease, Chinese Academy of Medical Sciences","place":["Beijing, China"]},{"name":"Department of Ophthalmology, Peking Union Medical College Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Eight-Year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunda","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengzhi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Pharmaceutical Sciences of Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of the Ministry of Education of China, Beijing Laboratory of Biomedical Materials","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.ai.2024.10.011","article-title":"Personalized precision: revolutionizing cancer treatment with mRNA-based vaccines in melanoma therapy","volume":"166","author":"Adhikary","year":"2025","journal-title":"Adv. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/pharmaceutics15071972","article-title":"Recent advancement in mRNA vaccine development and applications","volume":"15","author":"Al Fayez","year":"2023","journal-title":"Pharmaceutics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12575-021-00147-7","article-title":"Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines","volume":"23","author":"Azadi","year":"2021","journal-title":"Biol. Proced. Online"},{"key":"B4","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3390\/vaccines11030636","article-title":"Evolution and progress of mRNA vaccines in the treatment of melanoma: future prospects","volume":"11","author":"Bafaloukos","year":"2023","journal-title":"Vaccines."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e71187","DOI":"10.1002\/cam4.71187","article-title":"Promising cancer vaccine for glioblastoma therapy: a focus on mRNA vaccine","volume":"14","author":"Barati","year":"2025","journal-title":"Cancer Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2174\/0109298665402963251022054441","article-title":"mRNA-based cancer vaccines: a review of the current scenario and future prospects","volume":"32","author":"Bhattacharya","year":"2026","journal-title":"Protein Pept. Lett."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3390\/vaccines9101060","article-title":"mRNA-Based cancer vaccines: a therapeutic strategy for the treatment of melanoma patients","volume":"9","author":"Bidram","year":"2021","journal-title":"Vaccines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3390\/cancers17142356","article-title":"Cancer vaccination and immune-based approaches in pancreatic cancer","volume":"17","author":"Bloom","year":"2025","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1038\/s41598-025-89930-0","article-title":"Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice","volume":"15","author":"Boehm","year":"2025","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"h988","DOI":"10.1136\/bmj.h988","article-title":"Cancer vaccines","volume":"350","author":"Butterfield","year":"2015","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12951-025-03607-4","article-title":"Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy","volume":"23","author":"Cao","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/vaccines10122150","article-title":"mRNA-Based vaccines and therapeutics for COVID-19 and future pandemics","volume":"10","author":"Chavda","year":"2022","journal-title":"VACCINES."},{"key":"B16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/cam4.4633","article-title":"Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development","volume":"11","author":"Chen","year":"2022","journal-title":"Cancer Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e06426","DOI":"10.1002\/advs.202506426","article-title":"Rapid-turnaround co-administration of mRNA-based MHC-I and MHC-II-restricted neoantigens enhances immune responses of antigen-specific CD8+ T cells and anti-cancer efficacy in colorectal cancer","volume":"12","author":"Cho","year":"2025","journal-title":"Adv. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.3390\/cancers16193428","article-title":"Innovative cancer immunotherapy with MAGE-A3 mRNA cancer vaccines","volume":"16","author":"Choi","year":"2024","journal-title":"CANCERS"},{"key":"B21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1158\/0008-5472.CAN-24-4674","article-title":"Quantitative cell type-specific immunopeptidome analysis of macrophage and tumor coevolution reveals therapeutic MHC-I peptides in glioblastoma","volume":"85","author":"Cui","year":"2025","journal-title":"Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"eabn3464","DOI":"10.1126\/scitranslmed.abn3464","article-title":"Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice","volume":"15","author":"da Silva","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"975408","DOI":"10.3389\/fonc.2022.975408","article-title":"An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma","volume":"12","author":"Deng","year":"2022","journal-title":"Front. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1628583","DOI":"10.3389\/fimmu.2025.1628583","article-title":"A computational framework for optimizing mRNA vaccine delivery via AI-guided nanoparticle design and in silico gene expression profiling","volume":"16","author":"Di Salvatore","year":"2025","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.omto.2020.06.019","article-title":"CD133 mRNA-Loaded dendritic cell vaccination abrogates Glioma stem cell propagation in humanized glioblastoma mouse model","volume":"18","author":"Do","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"102702","DOI":"10.1016\/j.mtbio.2025.102702","article-title":"Activated T-cell membrane-derived nanocargoes displaying multi-immune checkpoints for enhanced cancer immunotherapy","volume":"36","author":"Du","year":"2026","journal-title":"Mater Today Bio"},{"key":"B28","doi-asserted-by":"publisher","first-page":"923647","DOI":"10.3389\/fimmu.2022.923647","article-title":"Potentialities and challenges of mRNA vaccine in cancer immunotherapy","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood.2025028597","article-title":"BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma","volume":"146","author":"Dutta","year":"2025","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1016\/j.ymthe.2025.04.044","article-title":"Therapeutic mRNA vaccine applications in oncology","volume":"33","author":"Elliott","year":"2025","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/vaccines13060588","article-title":"Next-generation vaccine platforms: integrating synthetic biology, nanotechnology, and systems immunology for improved immunogenicity","volume":"13","author":"Eslami","year":"2025","journal-title":"Vaccines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"eadn9961","DOI":"10.1126\/sciadv.adn9961","article-title":"Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity","volume":"10","author":"Fan","year":"2024","journal-title":"Sci. Adv."},{"key":"B33","doi-asserted-by":"publisher","first-page":"189493","DOI":"10.1016\/j.bbcan.2025.189493","article-title":"mRNA cancer vaccine: a novel and potential immunotherapy for multiple myeloma","volume":"1880","author":"Feng","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.1158\/0008-5472.CAN-21-3554","article-title":"Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in patients with cancer","volume":"81","author":"Figueiredo","year":"2021","journal-title":"Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1056\/NEJMra072739","article-title":"Cancer immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e010569","DOI":"10.1136\/jitc-2024-010569","article-title":"Leveraging mRNA technology for antigen based immuno-oncology therapies","volume":"13","author":"Floudas","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1021\/acs.molpharmaceut.3c00439","article-title":"Complex coacervates as a promising vehicle for mRNA delivery: a comprehensive review of recent advances and challenges","volume":"20","author":"Forenzo","year":"2023","journal-title":"Mol. Pharm."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e62889","DOI":"10.3791\/62889","article-title":"Synthesis and characterization of mRNA-loaded Poly(Beta aminoesters) nanoparticles for vaccination purposes","volume":"174","author":"Fornaguera","year":"2021","journal-title":"J. Vis. Exp."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1007\/s00432-022-04325-2","article-title":"Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development","volume":"149","author":"Fu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2021.06.020","article-title":"Synthetic modified messenger RNA for therapeutic applications","volume":"131","author":"Gao","year":"2021","journal-title":"Acta Biomater."},{"key":"B42","doi-asserted-by":"publisher","first-page":"9643","DOI":"10.7150\/thno.118976","article-title":"Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapy","volume":"15","author":"Gao","year":"2025","journal-title":"Theranostics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/vaccines13090986","article-title":"Individualized mRNA vaccines in melanoma-where do we stand?","volume":"13","author":"Gazouli","year":"2025","journal-title":"Vaccines"},{"key":"B44","doi-asserted-by":"publisher","first-page":"115315","DOI":"10.1016\/j.intimp.2025.115315","article-title":"In silico analysis of VEGFR2 and c-MET in consideration with immunologic facts: implications for mRNA vaccine design against breast cancer","volume":"164","author":"Ghayoumian","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/cac2.12453","article-title":"Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients","volume":"43","author":"Giuliano","year":"2023","journal-title":"Cancer Commun."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2410998","DOI":"10.1002\/adma.202410998","article-title":"A polymeric mRNA vaccine featuring enhanced site-specific mRNA delivery and inherent STING-stimulating performance for tumor immunotherapy","volume":"37","author":"Guo","year":"2025","journal-title":"Adv. Mater"},{"key":"B47","doi-asserted-by":"publisher","first-page":"114973","DOI":"10.1016\/j.addr.2023.114973","article-title":"Advances in mRNA therapeutics for cancer immunotherapy: from modification to delivery","volume":"199","author":"Han","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/pharmaceutics16010059","article-title":"Sensitizing the efficiency of ICIs by neoantigen mRNA vaccines for HCC treatment","volume":"16","author":"Han","year":"2024","journal-title":"Pharmaceutics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/pharmaceutics16070940","article-title":"\u03b1-Lactalbumin mRNA-LNP evokes an anti-tumor effect combined with surgery in triple-negative breast cancer","volume":"16","author":"He","year":"2024","journal-title":"Pharmaceutics"},{"key":"B50","doi-asserted-by":"publisher","first-page":"113788","DOI":"10.1016\/j.jconrel.2025.113788","article-title":"Amplifying STING activation by biomimetic manganese mRNA nanovaccines for local and systemic cancer immunotherapy","volume":"383","author":"He","year":"2025","journal-title":"J. Control Release"},{"key":"B51","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-021-01339-1","article-title":"Clinical and immunological effects of mRNA vaccines in malignant diseases","volume":"20","author":"Heine","year":"2021","journal-title":"Mol. Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"eabc7804","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e2207471","DOI":"10.1002\/adma.202207471","article-title":"An integrated polymeric mRNA vaccine without inflammation side effects for cellular immunity mediated cancer therapy","volume":"35","author":"Huang","year":"2023","journal-title":"Adv. Mater"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1097\/CM9.0000000000003455","article-title":"mRNA vaccines as cancer therapies","volume":"137","author":"Huang","year":"2024","journal-title":"Chin. Med. J. Engl."},{"key":"B56","doi-asserted-by":"publisher","first-page":"100469","DOI":"10.1016\/j.jgeb.2025.100469","article-title":"Personalized medicine in pancreatic cancer: harnessing the potential of mRNA vaccines","volume":"23","author":"Hussain","year":"2025","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.32607\/actanaturae.27707","article-title":"mRNA-Based personalized cancer vaccines: opportunities, challenges and outcomes","volume":"17","author":"Ibragimova","year":"2025","journal-title":"Acta Naturae"},{"key":"B58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.coviro.2021.03.008","article-title":"Future considerations for the mRNA-lipid nanoparticle vaccine platform","volume":"48","author":"Igy\u00e1rt\u00f3","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1501010","DOI":"10.3389\/fcimb.2024.1501010","article-title":"Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy","volume":"14","author":"Imani","year":"2025","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"pbae017","DOI":"10.1093\/pcmedi\/pbae017","article-title":"Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology","volume":"7","author":"Jacob","year":"2024","journal-title":"Precis. Clin. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.immuni.2018.02.010","article-title":"Understanding subset diversity in T cell memory","volume":"48","author":"Jameson","year":"2018","journal-title":"Immunity"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e202423280","DOI":"10.1002\/anie.202423280","article-title":"Innate immune activation with multifunctional nanoparticles for cancer immunotherapy","volume":"64","author":"Jiang","year":"2025","journal-title":"Angew. Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"15447","DOI":"10.1039\/d5tb01972a","article-title":"mRNA-LNP vaccines: rational design, delivery optimization, and clinical translation","volume":"13","author":"Jiang","year":"2025","journal-title":"J. Mater Chem. B"},{"key":"B64","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2024.04.039","article-title":"Emerging advances in delivery systems for mRNA cancer vaccines","volume":"370","author":"Jiang","year":"2024","journal-title":"J. Control Release"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2409914","DOI":"10.1002\/adma.202409914","article-title":"Transformable gel-to-nanovaccine enhances cancer immunotherapy via metronomic-like immunomodulation and collagen-mediated paracortex delivery","volume":"36","author":"Jin","year":"2024","journal-title":"Adv. Mater"},{"key":"B66","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/vaccines13020178","article-title":"In situ tumor vaccination using lipid nanoparticles to deliver Interferon-\u03b2 mRNA cargo","volume":"13","author":"Kimura","year":"2025","journal-title":"Vaccines"},{"key":"B67","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s44178-023-00042-z","article-title":"A personalized mRNA vaccine has exhibited potential in the treatment of pancreatic cancer","volume":"2","author":"Kang","year":"2023","journal-title":"Holist. Integr. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12951-024-02882-x","article-title":"Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials","volume":"22","author":"Karimi-Sani","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/pharmaceutics16040455","article-title":"Immune specific and tumor-dependent mRNA vaccines for cancer immunotherapy: reprogramming clinical translation into tumor editing therapy","volume":"16","author":"Katopodi","year":"2024","journal-title":"Pharmaceutics"},{"key":"B73","doi-asserted-by":"publisher","first-page":"27977","DOI":"10.1021\/acsnano.5c10648","article-title":"Modulating immunogenicity and reactogenicity in mRNA-Lipid nanoparticle vaccines through lipid component optimization","volume":"19","author":"Kawaguchi","year":"2025","journal-title":"ACS Nano"},{"key":"B74","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e0764","DOI":"10.1097\/PPO.0000000000000764","article-title":"Improving the efficacy of cancer mRNA vaccines","volume":"31","author":"Kirtane","year":"2025","journal-title":"Cancer J."},{"key":"B76","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.3390\/ijms26062453","article-title":"Deep clustering-based immunotherapy prediction for gastric cancer mRNA vaccine development","volume":"26","author":"Lan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"110529","DOI":"10.1016\/j.isci.2024.110529","article-title":"Multimodal analysis unveils tumor microenvironment heterogeneity linked to immune activity and evasion","volume":"27","author":"Lapuente-Santana","year":"2024","journal-title":"iScience"},{"key":"B80","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"109367","DOI":"10.1016\/j.intimp.2022.109367","article-title":"The main battlefield of mRNA vaccine - tumor immune microenvironment","volume":"113","author":"Li","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"973712","DOI":"10.3389\/fonc.2022.973712","article-title":"Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2095837","DOI":"10.1080\/21645515.2022.2095837","article-title":"The global mRNA vaccine patent landscape","volume":"18","author":"Li","year":"","journal-title":"Hum. VACCINES Immunother."},{"key":"B84","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/bs.ircmb.2022.04.011","article-title":"Advances in mRNA vaccines","volume":"372","author":"Li","year":"","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e1384","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/imm.13777","article-title":"Prevention and treatment of HPV-related cancer through a mRNA vaccine expressing APC-targeting antigen","volume":"172","author":"Li","year":"2024","journal-title":"Immunology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"217752","DOI":"10.1016\/j.canlet.2025.217752","article-title":"Cancer mRNA vaccines: clinical application progress and challenges","volume":"625","author":"Li","year":"2025","journal-title":"Cancer Lett."},{"key":"B88","doi-asserted-by":"publisher","first-page":"37280","DOI":"10.1038\/s41598-025-21238-5","article-title":"Flagellin co-expression potentiates mRNA vaccine-induced cytotoxic T lymphocyte responses but not anti-tumor immunity","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"B89","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/jnci\/djab174","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients","volume":"114","author":"Ligumsky","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"B90","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/vaccines12070727","article-title":"An overview of nanoparticle-based delivery platforms for mRNA vaccines for treating cancer","volume":"12","author":"Lin","year":"2024","journal-title":"VACCINES."},{"key":"B91","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.molcel.2021.11.019","article-title":"RNA circles with minimized immunogenicity as potent PKR inhibitors","volume":"82","author":"Liu","year":"2022","journal-title":"Mol. Cell"},{"key":"B92","doi-asserted-by":"publisher","first-page":"19550","DOI":"10.1021\/acsnano.3c05635","article-title":"mRNA cancer vaccines: construction and boosting strategies","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"B93","doi-asserted-by":"publisher","first-page":"189068","DOI":"10.1016\/j.bbcan.2023.189068","article-title":"Advances and prospects of mRNA vaccines in cancer immunotherapy","volume":"1879","author":"Liu","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"102803","DOI":"10.1016\/j.omtn.2025.102803","article-title":"Spleen-targeted mRNA delivery via long-chain PEGylated lipids at low molar ratio enhances antitumor immunity against melanoma","volume":"37","author":"Liu","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e19216","DOI":"10.1002\/anie.202519216","article-title":"Manganese-coordinated polyvalent aptameric system (COMPASS) enables DC-targeted mRNA\/Mn2 + co-delivery for cancer immunotherapy","volume":"16","author":"Liu","year":"2026","journal-title":"Angew. Chem."},{"key":"B96","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1080\/17425247.2022.2135502","article-title":"Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications","volume":"19","author":"Lopes","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"B98","doi-asserted-by":"publisher","first-page":"E450","DOI":"10.1016\/s1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1021\/acs.accounts.1c00601","article-title":"Non-liver mRNA delivery","volume":"55","author":"Loughrey","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.vaccine.2023.02.048","article-title":"In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer","volume":"41","author":"Lu","year":"2023","journal-title":"Vaccine"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e187405","DOI":"10.1172\/jci.insight.187405","article-title":"Enhanced durability of a Zika virus self-amplifying RNA vaccine through combinatorial OX40 and 4-1BB agonism","volume":"10","author":"Lu","year":"2025","journal-title":"JCI Insight"},{"key":"B102","doi-asserted-by":"publisher","first-page":"152399","DOI":"10.1016\/j.seminoncol.2025.152399","article-title":"Application prospects of tumor vaccines for pancreatic cancer: from TAAs to TSAs and combination strategies","volume":"52","author":"Lu","year":"2025","journal-title":"Semin. Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.3390\/ijms21145130","article-title":"Self-amplifying RNA viruses as RNA vaccines","volume":"21","author":"Lundstrom","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3390\/vaccines9101187","article-title":"Self-replicating RNA viruses for vaccine development against infectious diseases and cancer","volume":"9","author":"Lundstrom","year":"2021","journal-title":"Vaccines"},{"key":"B105","doi-asserted-by":"publisher","first-page":"114048","DOI":"10.1016\/j.jconrel.2025.114048","article-title":"Advances in RNA therapeutics and its delivery strategies against multiple myeloma","volume":"385","author":"Luo","year":"2025","journal-title":"J. Control. Release"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/cancers17111882","article-title":"Current progress and future perspectives of RNA-Based cancer vaccines: a 2025 update","volume":"17","author":"Magoola","year":"2025","journal-title":"Cancers"},{"key":"B108","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41434-022-00370-1","article-title":"Taylor dispersion analysis to support lipid-nanoparticle formulations for mRNA vaccines","volume":"30","author":"Malburet","year":"2023","journal-title":"Gene Ther."},{"key":"B109","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/82_2021_233","article-title":"Self-amplifying mRNA-Based vaccine technology and its mode of action","volume":"440","author":"Maruggi","year":"2022","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12029-025-01165-4","article-title":"Advances in vaccine-based therapies for pancreatic cancer","volume":"56","author":"McMillan","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"eadr2631","DOI":"10.1126\/sciadv.adr2631","article-title":"Generation of an inflammatory niche in a hydrogel depot through recruitment of key immune cells improves efficacy of mRNA vaccines","volume":"11","author":"Meany","year":"2025","journal-title":"Sci. Adv."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s10238-023-01020-5","article-title":"RNA modification in mRNA cancer vaccines","volume":"23","author":"Mei","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2100144","DOI":"10.1002\/adtp.202100144","article-title":"Virus-mimic mRNA vaccine for cancer treatment","volume":"4","author":"Meng","year":"2021","journal-title":"Adv. Ther."},{"key":"B114","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"B115","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/path.6083","article-title":"Fusion with type 2 macrophages induces melanoma cell heterogeneity that potentiates immunological escape from cytotoxic T lymphocytes","volume":"260","author":"Minowa","year":"2023","journal-title":"J. Pathol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/14760584.2023.2232450","article-title":"Emergence of mRNA vaccines in the management of cancer","volume":"22","author":"Mohamad Razif","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"B217","doi-asserted-by":"publisher","first-page":"8448","DOI":"10.3390\/ijms26178448","article-title":"Enhancing antitumor efficacy of MUC1 mRNA nano-vaccine by CTLA-4 siRNA-mediated immune checkpoint modulation in triple negative breast cancer mice model","volume":"26","author":"Monfaredan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/2159-8290.CD-NB2023-0028","article-title":"mRNA vaccine slows melanoma recurrence","volume":"13","year":"2023","journal-title":"Cancer Discov."},{"key":"B118","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10120-025-01640-8","article-title":"Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis","volume":"28","author":"Nagaoka","year":"2025","journal-title":"Gastric. Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1021\/acsabm.3c00721","article-title":"Advances in nonviral mRNA delivery materials and their application as vaccines for melanoma therapy","volume":"7","author":"Neill","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"key":"B120","doi-asserted-by":"publisher","first-page":"40733","DOI":"10.1021\/acsnano.5c14753","article-title":"Reprogramming immunosuppressive niches and the cancer immunity cycle in pancreatic cancer with neoantigen mRNA plus immune adjuvant nanocarrier strategies","volume":"19","author":"Nel","year":"2025","journal-title":"ACS Nano"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/vaccines11101599","article-title":"Advances in mRNA-based cancer vaccines","volume":"11","author":"Ni","year":"2023","journal-title":"Vaccines."},{"key":"B122","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"B123","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2023.11.003","article-title":"The potential of mRNA vaccines in cancer nanomedicine and immunotherapy","volume":"45","author":"Pan","year":"2024","journal-title":"Trends Immunol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B125","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1021\/acs.molpharmaceut.2c00738","article-title":"Poly(aspartic acid)-based polymeric nanoparticle for local and systemic mRNA delivery","volume":"19","author":"Park","year":"2022","journal-title":"Mol. Pharm."},{"key":"B126","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/978-1-0716-4742-4_16","article-title":"Lipid nanoparticles for the delivery of mRNA","volume":"2965","author":"Paroor","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1435480","DOI":"10.3389\/fonc.2024.1435480","article-title":"Lipids in the tumor microenvironment: immune modulation and metastasis","volume":"14","author":"Pascual","year":"2024","journal-title":"Front. Oncol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s11596-025-00112-5","article-title":"mRNA vaccines in cancer immunotherapy: recent advances, clinical translation, and future perspectives","volume":"45","author":"Pati","year":"2025","journal-title":"Curr. Med. Sci."},{"key":"B129","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design","volume":"198","author":"Pepini","year":"2017","journal-title":"J. Immunol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"103341","DOI":"10.1016\/j.drudis.2022.103341","article-title":"Self-amplifying mRNA vaccines: mode of action, design, development and optimization","volume":"27","author":"Pourseif","year":"2022","journal-title":"Drug Discov. Today"},{"key":"B131","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s11033-025-11421-2","article-title":"Neoantigen-driven cancer vaccines in personalized oncology: progress, obstacles, and translational prospects","volume":"53","author":"Prabhu","year":"2026","journal-title":"Mol. Biol. Rep."},{"key":"B132","doi-asserted-by":"publisher","first-page":"214667","DOI":"10.1016\/j.bioadv.2025.214667","article-title":"Recent advances in engineering approaches for delivery of mRNA-based therapeutics","volume":"182","author":"Prinindya","year":"2026","journal-title":"Biomater. Adv."},{"key":"B133","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41541-023-00733-8","article-title":"mRNA-LNP vaccination-based immunotherapy augments CD8+ T cell responses against HPV-positive oropharyngeal cancer","volume":"8","author":"Qiu","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/jpm14111092","article-title":"Advances in mRNA LNP-based cancer vaccines: mechanisms, formulation aspects, challenges, and future directions","volume":"14","author":"Ramadan","year":"2024","journal-title":"J. Pers. Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"B136","doi-asserted-by":"publisher","first-page":"e010249","DOI":"10.1136\/jitc-2024-010249","article-title":"Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression","volume":"12","author":"Roerden","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"B137","doi-asserted-by":"publisher","first-page":"144+","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41467-025-68080-x","article-title":"Optimal murine CD4+ T cell priming by mRNA-lipid nanoparticle vaccines requires endogenous antigen processing","volume":"17","author":"Rood","year":"2026","journal-title":"Nat. Commun."},{"key":"B139","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"B140","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3390\/pharmaceutics14081572","article-title":"mRNA-Loaded lipid nanoparticles targeting dendritic cells for cancer immunotherapy","volume":"14","author":"Sasaki","year":"2022","journal-title":"Pharmaceutics"},{"key":"B142","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"B143","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"B146","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41467-025-67331-1","article-title":"mRNA vaccine developed for sequential selective organ-to-cell targeting of glioma","volume":"17","author":"Shi","year":"2025","journal-title":"Nat. Commun."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1000681","DOI":"10.3389\/fimmu.2022.1000681","article-title":"Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: promising modality for future cancer immunotherapy","volume":"13","author":"Shou","year":"2022","journal-title":"Front. Immunol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"2002+","DOI":"10.1038\/s41591-021-01542-z","article-title":"Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors","volume":"27","author":"Shroff","year":"2021","journal-title":"Nat. Med."},{"key":"B149","doi-asserted-by":"publisher","first-page":"20240403","DOI":"10.1098\/rstb.2024.0403","article-title":"Does human cytomegalovirus provide a novel therapeutic target for patients with glioblastoma?","volume":"380","author":"S\u00f6derberg-Naucler","year":"2025","journal-title":"Philos. Trans. R. Soc. Lond B Biol. Sci."},{"key":"B150","doi-asserted-by":"publisher","first-page":"112037","DOI":"10.1016\/j.intimp.2024.112037","article-title":"The dawn of a new era: mRNA vaccines in colorectal cancer immunotherapy","volume":"132","author":"Song","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3390\/jpm14090993","article-title":"Effectiveness and safety of mRNA vaccines in the therapy of glioblastoma","volume":"14","author":"Strika","year":"2024","journal-title":"J. Pers. Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3390\/pharmaceutics17101327","article-title":"Unique features and collateral immune effects of mRNA-LNP COVID-19 vaccines: plausible mechanisms of adverse events and complications","volume":"17","author":"Szebeni","year":"2025","journal-title":"Pharmaceutics"},{"key":"B153","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11033-024-09418-4","article-title":"STING pathway as a cancer immunotherapy: progress and challenges in activating anti-tumor immunity","volume":"51","author":"Tabar","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"B154","doi-asserted-by":"publisher","first-page":"189333","DOI":"10.1016\/j.bbcan.2025.189333","article-title":"mRNA vaccines for prostate cancer: a novel promising immunotherapy","volume":"1880","author":"Tang","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B155","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13045-025-01694-2","article-title":"Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer","volume":"18","author":"Tang","year":"2025","journal-title":"J. Hematol. OncolJ Hematol. Oncol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737140.2025.2610271","article-title":"CRISPR-mRNA synergy: toward adaptive cancer immunotherapy","volume":"28","author":"Tanriverdi","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/17460441.2021.1935859","article-title":"An overview of rational design of mRNA-based therapeutics and vaccines","volume":"16","author":"To","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"B158","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/vaccines12060670","article-title":"mRNA technology and mucosal immunization","volume":"12","author":"Toniolo","year":"2024","journal-title":"Vaccines."},{"key":"B159","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B160","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13073-024-01281-z","article-title":"mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors","volume":"16","author":"Trivedi","year":"2024","journal-title":"Genome Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1013342","DOI":"10.3389\/fimmu.2023.1013342","article-title":"Incorporation of a TGF-\u03b22-inhibiting oligodeoxynucleotide molecular adjuvant into a tumor cell lysate vaccine to enhance antiglioma immunity in mice","volume":"14","author":"Tu","year":"2023","journal-title":"Front. Immunol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/jjco\/hyaf199","article-title":"Technological advances in mRNA delivery and engineering for therapeutic cancer vaccines","volume":"56","author":"Uchida","year":"2026","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/v17040566","article-title":"Self-amplifying RNA: advantages and challenges of a versatile platform for vaccine development","volume":"17","author":"Vallet","year":"2025","journal-title":"Viruses"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1029069","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front. Immunol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1002350","DOI":"10.37349\/etat.2025.1002350","article-title":"Cancer vaccines: advances, hurdles, and future directions","volume":"6","author":"Vlachostergios","year":"2025","journal-title":"Explor Target Anti-Tumor Ther."},{"key":"B167","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/pharmaceutics14030512","article-title":"Nonviral delivery systems of mRNA vaccines for cancer gene therapy","volume":"14","author":"Wang","year":"2022","journal-title":"Pharmaceutics"},{"key":"B168","doi-asserted-by":"publisher","first-page":"16744","DOI":"10.1038\/s41598-023-43898-x","article-title":"Elucidation of lipid nanoparticle surface structure in mRNA vaccines","volume":"13","author":"Wang","year":"2023","journal-title":"Sci. Rep."},{"key":"B169","doi-asserted-by":"publisher","first-page":"e2311276120","DOI":"10.1073\/pnas.2311276120","article-title":"Biomimetic noncationic lipid nanoparticles for mRNA delivery","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B170","doi-asserted-by":"publisher","first-page":"173","DOI":"10.21037\/tcr-23-1237","article-title":"Preparation of hepatocellular carcinoma mRNA vaccines based on potential tumor targets and immunophenotypes","volume":"13","author":"Wang","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"B171","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.2147\/IJN.S520329","article-title":"Nanoformulations downregulating METTL16 combined with mRNA tumor vaccines suppress triple-negative breast cancer and prevent metastasis","volume":"20","author":"Wang","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"B172","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"B173","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3390\/vaccines13080882","article-title":"Decrypting the immune symphony for RNA vaccines","volume":"13","author":"Weidensee","year":"2025","journal-title":"Vaccines"},{"key":"B174","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"B175","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA circularization diminishes immunogenicity and can extend translation duration in vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Mol. Cell"},{"key":"B176","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"e1978","DOI":"10.1002\/wnan.1978","article-title":"An overview of lipid constituents in lipid nanoparticle mRNA delivery systems","volume":"16","author":"Wu","year":"2024","journal-title":"Wiley Interdiscip. Rev. Nanomed Nanobiotechnol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1039\/d4nr00019f","article-title":"Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines","volume":"16","author":"Wu","year":"2024","journal-title":"Nanoscale"},{"key":"B179","doi-asserted-by":"publisher","first-page":"8268","DOI":"10.1039\/d5tb00995b","article-title":"Harnessing dendritic cells as immunological bridges to potentiate mRNA cancer vaccines","volume":"13","author":"Wu","year":"2025","journal-title":"J. Mater Chem. B"},{"key":"B180","doi-asserted-by":"publisher","first-page":"125520","DOI":"10.1016\/j.ijpharm.2025.125520","article-title":"Process development of tangential flow filtration and sterile filtration for manufacturing of mRNA-lipid nanoparticles: a study on membrane performance and filtration modeling","volume":"675","author":"Wu","year":"2025","journal-title":"Int. J. Pharm."},{"key":"B181","doi-asserted-by":"publisher","first-page":"e202503297","DOI":"10.1002\/anie.202503297","article-title":"A light-driven electrochromic materials-based nanomotor for H2S-controlled drug release in synergistic cancer chemotherapy immunotherapy","volume":"64","author":"Wu","year":"2025","journal-title":"Angew. Chem."},{"key":"B182","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/cancers18010144","article-title":"Advances in neoantigen-based cancer vaccines","volume":"18","author":"Wu","year":"2025","journal-title":"Cancers"},{"key":"B183","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12951-025-03681-8","article-title":"Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma model","volume":"23","author":"Wu","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"2373526","DOI":"10.1080\/2162402X.2024.2373526","article-title":"Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity","volume":"13","author":"Xu","year":"2024","journal-title":"Oncoimmunology"},{"key":"B185","doi-asserted-by":"publisher","first-page":"e2202688","DOI":"10.1002\/adhm.202202688","article-title":"Polymer-based mRNA delivery strategies for advanced therapies","volume":"12","author":"Yang","year":"2023","journal-title":"Adv. Healthc. Mater"},{"key":"B186","doi-asserted-by":"publisher","first-page":"11679","DOI":"10.1021\/jacs.3c14010","article-title":"Biodegradable lipid-modified Poly(Guanidine thioctic acid)s: a fortifier of lipid nanoparticles to promote the efficacy and safety of mRNA cancer vaccines","volume":"146","author":"Yang","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"B187","doi-asserted-by":"publisher","first-page":"e70041","DOI":"10.1002\/cai2.70041","article-title":"mRNA cancer vaccines: from pandemic paradigm to personalized oncology therapeutics","volume":"4","author":"Yang","year":"2025","journal-title":"Cancer Innov."},{"key":"B188","doi-asserted-by":"publisher","first-page":"2307187","DOI":"10.1080\/21645515.2024.2307187","article-title":"Recent progress in mRNA cancer vaccines","volume":"20","author":"Yao","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"B189","doi-asserted-by":"publisher","first-page":"100562","DOI":"10.1016\/j.medj.2024.11.015","article-title":"Clinical advances of mRNA vaccines for cancer immunotherapy","volume":"6","author":"Yaremenko","year":"2025","journal-title":"Med"},{"key":"B190","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/v16040503","article-title":"Trans-amplifying RNA: a journey from alphavirus research to future vaccines","volume":"16","author":"Y\u0131ld\u0131z","year":"2024","journal-title":"Viruses"},{"key":"B191","doi-asserted-by":"publisher","first-page":"2403366","DOI":"10.1002\/adhm.202403366","article-title":"Novel less toxic, lymphoid tissue-targeted lipid nanoparticles containing a vitamin B5-Derived ionizable lipid for mRNA vaccine delivery","volume":"14","author":"Yoo","year":"2025","journal-title":"Adv. Healthc. Mater"},{"key":"B192","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11033-023-09096-8","article-title":"Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy","volume":"51","author":"Zafar","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"B193","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"B194","doi-asserted-by":"publisher","first-page":"128061","DOI":"10.1016\/j.vaccine.2025.128061","article-title":"Distinct innate immune activation profiles of an mRNA-lipid nanoparticle vaccine compared to the empty lipid nanoparticle","volume":"71","author":"Zelkoski","year":"2026","journal-title":"Vaccine"},{"key":"B195","doi-asserted-by":"publisher","first-page":"123615","DOI":"10.1016\/j.biomaterials.2025.123615","article-title":"Cancer vaccines: discovery, development, and challenges for clinical translation","volume":"325","author":"Zhang","year":"2026","journal-title":"Biomaterials"},{"key":"B196","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1080\/21645515.2021.1921524","article-title":"RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy","volume":"17","author":"Zhang","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"B197","doi-asserted-by":"publisher","first-page":"e2005191118","DOI":"10.1073\/pnas.2005191118","article-title":"Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through toll-like receptor 4 signaling","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B198","doi-asserted-by":"publisher","first-page":"967505","DOI":"10.3389\/fimmu.2022.967505","article-title":"Application of lipid-based nanoparticles in cancer immunotherapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"2202412","DOI":"10.1002\/adhm.202202412","article-title":"Antitumor activity of Anti-miR-21 delivered through lipid nanoparticles","volume":"12","author":"Zhang","year":"2023","journal-title":"Adv. Healthc. Mater"},{"key":"B200","doi-asserted-by":"publisher","first-page":"115361","DOI":"10.1016\/j.biopha.2023.115361","article-title":"mRNA vaccine in gastrointestinal tumors: immunomodulatory effects and immunotherapy","volume":"166","author":"Zhang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B201","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1021\/acsomega.3c08353","article-title":"Lipid nanoparticle-based delivery System-A competing place for mRNA vaccines","volume":"9","author":"Zhang","year":"2024","journal-title":"ACS Omega"},{"key":"B202","doi-asserted-by":"publisher","first-page":"2307225","DOI":"10.1002\/advs.202307225","article-title":"Photosynthetic bacteria-hitchhiking 2D iMXene-mRNA vaccine to enable photo-immunogene cancer therapy","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv. Sci."},{"key":"B203","doi-asserted-by":"publisher","first-page":"eadx5970","DOI":"10.1126\/sciadv.adx5970","article-title":"Ionizable guanidine-based lipid nanoparticle for targeted mRNA delivery and cancer immunotherapy","volume":"11","author":"Zhang","year":"2025","journal-title":"Sci. Adv."},{"key":"B204","doi-asserted-by":"publisher","first-page":"2412654","DOI":"10.1002\/adma.202412654","article-title":"STING-activating polymers boost lymphatic delivery of mRNA vaccine to potentiate cancer immunotherapy","volume":"37","author":"Zhang","year":"2025","journal-title":"Adv. Mater."},{"key":"B205","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ymthe.2025.09.032","article-title":"A STING agonist potentiates C1 lipidoid-based mRNA cancer vaccine through promoting TNF-\u03b1 secretion in vivo","volume":"34","author":"Zhang","year":"2026","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B206","doi-asserted-by":"publisher","first-page":"189515","DOI":"10.1016\/j.bbcan.2025.189515","article-title":"Advancements in breast cancer mRNA vaccines: current development and future prospects","volume":"1881","author":"Zheng","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B207","doi-asserted-by":"publisher","first-page":"709986","DOI":"10.3389\/fimmu.2021.709986","article-title":"Dissecting tumor antigens and immune subtypes of glioma to develop mRNA vaccine","volume":"12","author":"Zhong","year":"2021","journal-title":"Front. Immunol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.actbio.2025.08.005","article-title":"Macroporous hydrogel-based mRNA cancer vaccine for in situ recruitment and modulation of dendritic cells","volume":"204","author":"Zhou","year":"2025","journal-title":"Acta Biomater."},{"key":"B209","doi-asserted-by":"publisher","first-page":"102623","DOI":"10.1016\/j.omtn.2025.102623","article-title":"Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines","volume":"36","author":"Zhou","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B210","doi-asserted-by":"publisher","first-page":"101603","DOI":"10.1016\/j.mtbio.2025.101603","article-title":"PD-L1 siRNA incorporation into a cationic liposomal tumor mRNA vaccine enhances cytotoxic T cell activation and prevents immune evasion","volume":"31","author":"Zhou","year":"2025","journal-title":"Mater Today Bio"},{"key":"B211","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jpha.2023.04.012","article-title":"Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C","volume":"13","author":"Zhu","year":"2023","journal-title":"J. Pharm. Anal."},{"key":"B216","doi-asserted-by":"publisher","first-page":"651","DOI":"10.7150\/thno.123633","article-title":"Tumor mRNA-lipid nanoparticles via chimeric nanobody-lipid co-assembly","volume":"16","author":"Zhu","year":"2026","journal-title":"Theranostics"},{"key":"B212","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3390\/cells14181476","article-title":"Next-generation mRNA vaccines in melanoma: advances in delivery and combination strategies","volume":"14","author":"Zoroddu","year":"2025","journal-title":"Cells"},{"key":"B213","doi-asserted-by":"publisher","first-page":"17309","DOI":"10.1021\/acsnano.4c14573","article-title":"Glioblastoma cell derived exosomes as a potent vaccine platform targeting primary brain cancers and brain metastases","volume":"19","author":"Zou","year":"2025","journal-title":"ACS Nano"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1852041\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:29:52Z","timestamp":1783409392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1852041\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":216,"alternative-id":["10.3389\/fphar.2026.1852041"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1852041","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1852041"}}